Protocol Ledger

NCT07157774 · Phase III · RECRUITING

Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a)

Interventional Phase III clinical trial protocol NCT07157774 sponsored by Eli Lilly and Company in Cardiovascular and Thrombosis, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2025-09-02 Enrollment: 10,450 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT07157774
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)10,450 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)0 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07157774
Protocol FieldVerified Registry Value
NCT IdentifierNCT07157774
Consolidated Lead SponsorEli Lilly and Company
Therapeutic Condition CohortCardiovascular and Thrombosis
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment10,450 participants (ESTIMATED)
Registered Start Date2025-09-02
WhyStopped ClassificationNot Stopped

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Eli Lilly and Company across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Cardiovascular and Thrombosis Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI